University Hospital Tuebingen

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 1388-01-01

Employees: -

Market Cap: -

Website: https://www.klinikum.uni-heidelberg.de/Startseite.2.0.html?&no_cache=1

Clinical Trials

Kids Obesity Prevention Program - Study (KOP)

Not Applicable

Completed

Conditions: Obesity
Child

Interventions: Other: The serious game KOP

First Posted Date: 2015-09-16

Last Posted Date: 2015-11-30

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 60

Registration Number: NCT02551978

Metabolic Effects of Choline and Docosahexaenoic Acid Supplementation in Preterm Infants

Not Applicable

Completed

Conditions: Infant, Premature

Interventions: Dietary Supplement: DHA supplementation
Dietary Supplement: choline supplementation
Dietary Supplement: standard nutrition

First Posted Date: 2015-07-28

Last Posted Date: 2018-05-15

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 24

Registration Number: NCT02509728

Locations: 🇩🇪
University Hospital of Tuebingen, Tuebingen, Germany

Adjuvant Psychotherapy for Relapse Prevention in Early Adulthood (< 35 yr.) of Bipolar Disorder

Not Applicable

Completed

Conditions: Bipolar Disorder

Interventions: Behavioral: SEKT - Cognitive-Behavioral-Emotional
Behavioral: FEST - Clinical Supportive Educational

First Posted Date: 2015-07-23

Last Posted Date: 2020-11-04

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 318

Registration Number: NCT02506322

Locations: 🇩🇪
Eberhard Karls University, Tuebingen, Germany

Influence of Central Nervous Insulin Action on Insulin Sensitivity of Peripheral Organs in Lean Versus Overweight Humans

Not Applicable

Completed

Conditions: Insulin Resistance

Interventions: Drug: human insulin

First Posted Date: 2015-06-11

Last Posted Date: 2016-01-08

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 21

Registration Number: NCT02468999

Locations: 🇩🇪
University of Tuebingen, Department of Internal Medicine IV, Tübingen, Germany

Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)

Phase 2

Conditions: Malignant Melanoma
Metastases

Interventions: Drug: Buparlisib

First Posted Date: 2015-05-22

Last Posted Date: 2017-05-03

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 22

Registration Number: NCT02452294

Locations: 🇩🇪
Department of Dermatology, University Hospital, Tuebingen, Germany
🇩🇪
Department of Dermatology, University Hopsital, Dresden, Germany

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

Phase 1

Conditions: Recurrent Prostate Cancer

Interventions: Biological: Peptide vaccine
Drug: Montanide ISA-51
Procedure: local hyperthermia
Drug: Granulocyte macrophage colony stimulating factor (GM-CSF)
Drug: mRNA
Drug: Imiquimod
Drug: Protamin

First Posted Date: 2015-05-22

Last Posted Date: 2017-08-17

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 36

Registration Number: NCT02452307

Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)

Not Applicable

Completed

Conditions: Melanoma

Interventions: Procedure: Clinical Monitoring (Palpation and node ultrasound)
Procedure: Completion Lymphadenectomy

First Posted Date: 2015-05-05

Last Posted Date: 2022-12-21

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 483

Registration Number: NCT02434107

Locations: 🇩🇪
Städtische Kliniken Darmstadt, Darmstadt, Germany
🇩🇪
Ludwig-Maximilians-Universität, Munich, Germany
🇩🇪
Universitätsklinkum Münster, Münster, Germany

and more 38 locations

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides

Phase 1

Conditions: Renal Cell Cancer
Advanced Renal Cell Cancer

Interventions: Biological: peptide vaccine
Drug: Granulocyte Macrophage Colony Stimulating Factor
Drug: Montanide ISA-51

First Posted Date: 2015-04-29

Last Posted Date: 2017-08-17

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 40

Registration Number: NCT02429440

Pre-meal Planning and Expected Satiety

Conditions: Adiposity

First Posted Date: 2015-04-27

Last Posted Date: 2017-05-31

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 60

Registration Number: NCT02427152

Locations: 🇩🇪
University Clinic of Tuebingen, fMEG Center, Tuebingen, Germany

Apixaban for Treatment of Embolic Stroke of Undetermined Source

Phase 3

Completed

Conditions: Embolic Stroke of Undetermined Source

Interventions: Drug: Aspirin
Drug: Apixaban

First Posted Date: 2015-04-27

Last Posted Date: 2021-10-13

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 352

Registration Number: NCT02427126

Locations: 🇩🇪
Regiomed Kliniken Coburg GmbH Abt. II, Coburg, Germany
🇩🇪
Neurologie, Klinikum Friedrichshafen GmbH, Friedrichshafen, Germany
🇩🇪
Carl von Basedow KlinikumSaalekreis gGmbH, Merseburg, Germany

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy